The Latest Breaking News from Novo Nordisk

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

In today’s newsletter: Semaglutide has won endorsements from celebrities and expert drugs advisers and has gone viral on TikTok. But don’t expect a quick fix

Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year.

Balanced diet and exercise remain key to losing weight, health body says

New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.

Novo Nordisk stock slumped Thursday after its weight loss blockbuster, Wegovy, missed sales expectations despite rocketing demand.

Drug shortages are growing in the United States, and experts see no clear path to resolving them

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17